Bristol-Myers Squibb: Too Many Headwinds To Ignore, Despite The Stellar
BMY remains a speculative dividend play here, with it remaining to be seen when the correction may end and if the floor may hold at $48s. While Revlimid's top-line erosion appears to be deceleratin...
Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash
Stephanie Link and Jim Lebenthal join 'Halftime Report' to discuss Bristol Myers Squibb's latest announcement to buy Karuna Therapeutics for $14 billion.
Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal
Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP) announced a deal to acquire the co...
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
Midday Movers: Karuna Jumps on Deal With Bristol Myers Squibb, Nike Falls on Sales Outlook
U.S. equities headed into the long holiday weekend with gains at midday, amid a broad-based rally fueled by enthusiasm over the possibility of several Fed interest rate cuts next year. The Dow, S&P...
Bristol Myers Squibb Boosts Its Neuroscience Reach With $14 Billion Karuna Deal
Karuna Therapeutics (KRTX) shares skyrocketed over 46% after Bristol Myers Squibb (BMY) said it would buy the biopharmaceutical firm for $14 billion to expand its neuroscience portfolio.
Bristol-Myers Jumps on Billion-Dollar Buzz
Bristol-Myers Squibb Co (NYSE:BMY) stock is on the rise today, up 2.8% at $52.71 at last glance, after news that the biopharmaceutical company is acquiring Karuna (KRTX) for $14 billion.
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.
A Major Acquisition and Other News Ahead of the Holiday Weekend
Before U.S. markets opened on Friday, the Bureau of Economic Analysis released its personal income and spending report for November.
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.
Bristol Myers to buy Karuna Therapeutics for $14B
Karuna's crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.
Bristol Myers to buy Karuna Therapeutics for $14 billion
CNBC's Joe Kernen reports on the latest news.
Bristol Myers to Buys Karuna Therapeutics in $14 Billion Pharma Deal: Report
Karuna has an experimental schizophrenia drug called KarXT up for U.S. government approval.
Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference.
Karuna Therapeutics' stock rockets into record territory after report Bristol Myers' $14 billion buyout agreement
Shares of Karuna Therapeutics Inc. KRTX, +1.80% rocketed 33.8% into record territory in premarket trading Friday, after The Wall Street Journal reported that Bristol Myers Squibb Co. BMY, +0.59% ha...
Related Companies